Treatment options for benign prostatic hyperplasia.
OBJECTIVE
To examine current treatment options for benign prostatic hyperplasia with emphasis on randomized, clinical trials and our current management approach.


METHODS
Benign prostatic hyperplasia remains difficult to define clinically or measure objectively. As a result, research has been fairly weak. With newer treatments, however, more definitive studies have been reported.


RESULTS
Transurethral resection of the prostate remains the criterion standard for severe disease. Watchful waiting, medical management, or early surgical intervention are all valid options for moderate disease and should be tailored to the characteristics and desires of individual patients. Recent minimally invasive surgical techniques, such as microwave and laser surgery, have not yet achieved the quality of evidence to be generally recommended.


CONCLUSIONS
Management of benign prostatic hyperplasia should be individualized to patients' circumstances and personal choices.
Portis
A J
AJ
University of Alberta, Edmonton.
Mador
D R
DR
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D003663:Decision Trees; D006801:Humans; D006979:Hyperthermia, Induced; D053685:Laser Therapy; D008297:Male; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000150:complications / Q000628:therapy*; D015607:Stents
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists